Recent developments of targeted therapies in the treatment of non-small cell lung cancer

Current Drug Discovery Technologies

Volumn 6, Issue 2, 2009, Pages 91-102

  Rossi, Antonio ^a   Maione, Paolo ^a   Colantuoni, Giuseppe ^a   Ferrara, Carmine ^a   Rossi, Emanuela ^a   Guerriero, Ciro ^a   Nicolella, Dario ^a   Falanga, Marzia ^a   Palazzolo, Giovanni ^b   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b Division of Medical Oncology   (Italy)

Author keywords

Bevacizumab; EGFR; Erlotinib; NSCLC; VEGF; ZD6474

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; ROFECOXIB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CORNEA ULCER; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; FATIGUE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RASH; RECURRENT CANCER; REVIEW; STOMATITIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 67649204708     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309788488339     Document Type: Review

References (84)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J.: Cancer statistics, 2008. CA. Cancer J. Clin. 58(1), 71-96, (2008).
2. Parkin D.M., Bray F., Ferlay J., Pisani P.: Global cancer statistics, 2002. CA. Cancer J. Clin. 55(2), 74-108, (2005).
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98, (2002).
4. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551, (2008).
5. Normanno N., Bianco C., De Luca A., Maiello M.R., Salomon D.S.: Target-based agent against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 10(1), 1-21, (2003).
6. Mendelson J.: Blockade of receptors for growth factor: an anticancer therapy. Clin. Cancer Res. 6(5), 747-753, (2000).
7. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E.: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159-3167, (2000).
8. Yarden Y., Sliwkowski M.X.: Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2(2), 127-137, (2001).
9. Kurie J.M., Shin H.J., Lee J.S., Morice R.C., Ro J.Y., Lippman S.M., Hittelman W.N., Yu R., et al.: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin. Cancer Res. 2(10), 1787-1793, (1996).
10. Hidalgo M., Bloedow D: Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin. Oncol. 30 (Suppl 7), 25-33, (2003).
11. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., Kris M.G., Tran H.T., et al.: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899, (2005).
12. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., Milanowski J., Karnicka-Mlodkowski H., et al.: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545-1552, (2007).
13. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., Levitan N., Gressot L., et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095-2103, (2000).
14. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., Kalman L., Miller V., et al.: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18(12), 2354-2362, (2000). Erratum in: J. Clin. Oncol. 22(1), 209, (2004).
15. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., Gatzemeier U., Tsao T.C., et al.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597, (2004).
16. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132, (2005).
17. Bezjak A., Tu D., Seymour L., Clark G., Trajcovic A., Zukin M., Ayoub J., Lago S., et al.: Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the national cancer institute of canada clinical trials group study BR.21. J. Clin. Oncol. 24(24), 3831-3837, (2006). Erratum in: J. Clin. Oncol. 25(1), 167, (2007).
18. Clark G.M., Zborowski D.M., Santabarbara P., Ding K., Whitehead M., Seymour L., Shepherd F.A.: Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Groupstudy BR.21. Lung Cancer 7(6), 389-394, (2006).
19. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., Siu L.L.: Multicenter phase II study of erlotinib, an oral epidermal tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of cancer of the head and neck. J. Clin. Oncol. 22(1), 77-85, (2004).
20. Amador M.L., Oppenheimer D., Perea S., Maitra A., Cusati G., Iacobuzio-Donahue C., Baker S.D., Ashfaq R., et al.: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64(24), 9139-9143, (2004).
21. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., Fong K.M., Lee H., et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 97(5), 339-346, (2005).
22. Janne P.A., Engelman J.A., Johnson B.E.: Epidermal growth factor receptor mutations in non-small-cell lung: implications for treatment and tumor biology. J. Clin. Oncol. 23(14), 3227-3234, (2005).
23. Giaccone G.: Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J. Clin. Oncol. 23(14), 3235-3242, (2005).
24. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., Lorimer I., Zhang T., et al.: Erlotinib in lung cancer: molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133-144, (2005). Erratum in: N. Engl. J. Med. 355(16), 1746, (2006).
25. Gandara D.R., Gumerlock P.H.: Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out? J. Clin. Oncol. 23(25), 5856-5858, (2005).
26. Jackman D.M., Yeap Y.B., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., Bell D.W., Huberman M.S., et al.: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small-cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 12(13), 3908-3914, (2006).
27. Hirsch F.R., Varella-Garcia M., Bunn P.A.Jr., Di Maria M.V., Veve R., Bremmes M.R., Baron A.E., Zeng C., et al.: Epidermal growth factor receptor in non-small-cell-lung-carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21(20), 3798-3807, (2003).
28. Dziadziuszko R., Holm B., Skov B.G., Osterlind K., Sellers M.V., Franklin W.A., Bunn P.A.Jr., Varrella-Garcia M., et al.: Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non small cell lung cancer patients treated with chemotherapy. Ann. Oncol. 18(3), 447-452, (2007).
29. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., et al.: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101(36), 13306-13311, (2004).
30. Ahrendt S.A., Decker P.A., Alawi E.A., Zhu Yr. Y.R., Sanches- Cespedes M., Yang S.C., Haasler G.B., Kajdacsy-Balla A., et al.: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92(6), 1525-1530, (2001).
31. Rodenhuis S., Slebos R.J., Boot A.J., Evers S.G., Mooi W.J., Wagenaar S.S., van Bodegom P.C., Bos J.L.: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 48(20), 5738-5741, (1988).
32. Suzuki Y., Orita M., Shiraishi M., Hayashi K., Sekiya T.: Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 5(7), 1037-1043, (1990).
33. Zhu C., da Cunha Santos G., Ding K., Sakurada A., Cutz J.C., Liu N., Zhang T., Marrano P. et al.: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 26(26), 4268-4275 (2008).
34. Pao W., Miller W.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73, (2005).
35. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786-792, (2005).
36. Gridelli C., Rossi A., Mongillo F., Bareschino M., Maione P., Ciardiello F.: A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clin. Lung Cancer 8, 396-398, (2007).
37. Bergers G., Benjamin L.E.: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3(6), 401-410, (2003).
38. Hicklin D.J., Ellis L.M.: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027, (2005).
39. Ushijima C., Tsukamoto S., Yamazaki K., Yoshino I., Sugio K., Sugimachi K.: High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer 34(2), 233-241, (2001).
40. Ferrara N., Gerber H.P., LeCouter J.: The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676, (2003).
41. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W.: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5(12), 1806-1814, (1991).
42. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., Abraham J.A.: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266(18), 11947-11954, (1991).
43. Brown L.F., Yeo K.T., Berse B., Yeo T.K., Senger D.R., Dvorak H.F., van de Water R.: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176(5), 1375-1379, (1992).
44. Fukumura D., Xu L., Chen Y., Gohongi T., Seed B., Jain R.K.: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61(16), 6020-6024, (2001).
45. Rak J., Yu J.L., Klement G., Kerbel R.S.: Oncogenes and angiogenesis: Signalling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc. 5(1), 24-33, (2000).
46. Ferrara N.: Vascular endothelial growth factor. Trends Cardiovasc. Med. 3(6), 244-250, (1993).
47. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., Breitman M., Alitalo K.: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA 92(8), 3566-3570, (1995).
48. Paavonen K., Puolakkainen P., Jussila L., Jahkola T., Alitalo K.: Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156(5), 1499-1504, (2000).
49. Millauer B., Longhi M.P., Plate K.H., Shawver L.K., Risau W., Ullrich A., Strawn L.M.: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56(7), 1615-1620, (1996).
50. Zebrowski B.K., Yano S., Liu W., Shaheen R.M., Hicklin D.J., Putnam J.B. Jr., Ellis L.M.: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. 5(11), 3364-3368, (1999).
51. Zebrowski B.K., Liu W., Ramirez K., Akagi Y, Mills G.B., Ellis L.M.: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 6(4), 373-378, (1999).
52. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., Ferrara N.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593-4599, (1997).
53. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342, (2004).
54. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H.: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550, (2006). Erratum in: N. Engl. J. Med. 356(3), 318, (2007).
55. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., Langer C.J., de Vore R.F. 3rd, et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191, (2004).
56. Manegold C., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., Leighl N., Mezger J. et al.: BO17704 (AVAIL): A phase II randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann. Oncol. 19 (Suppl. 8), viii1 (Abstr. LBA1), (2008).
57. Lilenbaum R., Raez L., Tseng J., Seigel L., Davila E.: Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J. Thor. Oncol. 3(5), 511-515, (2008).
58. William W.N. Jr., Kies M.S., Fossella S.V., Gladish G., Heymach J.V., Glisson B.S., Tse W.H., Liu D., et al.: Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(18S), 691s (Abstr. 18098), (2007).
59. Patel J.D., Hensing T.A., Villafor V., Hart E., Bonomi P.: Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results. J. Clin. Oncol. 25(18S), 409s (Abstr. 7601), (2007).
60. Dalsania C.J., Hageboutros A., Harris E., Krieger K., Vora C., Stevenson J.: Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer. J. Clin. Oncol. 25(18S), 697s (Abstr. 18163), (2007).
61. Waples J.M., Auerbach M., Boccia R., Wiggans R.G., Steis R.: A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer. J. Clin. Oncol. 25(18S), 685s (Abstr. 18025), (2007).
62. Heist R.S., Fidias P., Huberman M., Temel J., Sequist L., Lynch T.J.: Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(18S), 434s (Abstr. 7700), (2007).
63. Reynolds C., Barrera D., Vu D.Q., Jotte R., Spira A.I., Weissmann C.H., Boehm K.A., Ilegbodu D., et al.: An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(18S), 411s (Abstr. 7610), (2007).
64. Havlik R.J., Yancik R., Long S., Ries L., Edwards B.: The National Cancer Institute on Aging and the National Cancer Institute SEER. Collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 74 (Suppl 7), 2101-2106, (1994).
65. Merza T., Howard L.M., Junagadhwalla M., Gajra A.: Exclusions to use of bevacizumab in elderly veterans with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(18S), 687s (Abstr. 18046), (2007).
66. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., Barbera S., Ferrau F., et al.: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J. Natl. Cancer Inst. 95(5), 362-372, (2003).
67. Ramalingam S.S., Dahlberg S.E., Langer C.J., Gray R., Belani C.P., Brahmer J.R., Sandler A., Schiller J.H., et al.: Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J. Clin. Oncol. 26(1), 60-65, (2008).
68. Brahmer J.R., Gray R., Schiller J.H., Perry M., Sandler A., Johnson D.: ECOG 4599 phase III trial of carboplatin and paclitaxel ± bevacizumab: Subset analysis of survival by gender. J. Clin. Oncol. 24(18S), 373s (Abstr. 7036), (2006).
69. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H.: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizuma - an Eastern Cooperative Oncology Group Study. Clin. Cancer Res. 14(5), 1407-1412, (2008).
70. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., Boffey S.J., Valentine P.J., et al.: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62(16), 4645-4655, (2002).
71. Ciardiello F., Caputo R., Damiano V., Caputo R., Troiani T., Vitagliano D., Carlomagno F., Veneziani B.M., et al.: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9(4), 1546-1556, (2003).
72. Carlomagno F., Vitagliano D., Guida T., Ciardiello F., Tortora G., Vecchio G., Ryan A.J., Fontanini G., et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62(24), 7284-7290, (2002).
73. Holden S.N., Eckhardt S.G., Basser R., de Boer R., Rischin D., Green M., Rosenthal M.A., Wheeler C., et al.: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF signalling, in patients with solid, malignant tumors. Ann. Oncol. 16(8), 1391-1397, (2005).
74. Tamura T., Minami H., Yamada Y., Yamamoto N., Shimoyama T., Murakami H., Horiike A., Fujisaka Y. et al.: A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J. Thor. Oncol. 1(9), 1002-1009, (2006).
75. De Boer R., Vansteenkiste J., Humblet Y., Wolf J., Nogova L., Ruffert K., Smith R., Godwood A., et al.: Vandetanib with pemetrexed in patients with previously treated non-small cell lung cancer (NSCLC): An open-label, multicenter phase I study. J. Clin. Oncol. 25(18S), 422s (Abstr. 7654), (2007).
76. Kiura K., Nakagawa K., Shinkai T., Eguchi K., Ohe Y., Yamamoto N., Tsuboi M., Yokota S., et al.: A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J. Thor. Oncol. 3(4), 386-393, (2008).
77. Natale R.B., Bodkin D., Govindan R., Sleckman B., Rizvi N., Capo A., Germonprè P., Stockman P., et al.: ZD 6474 versus gefitinib in patients with advanced NSCLC: Final results from a two part, double blind, randomized phase II trial. J. Clin. Oncol. 24(18S), 364s (Abstr. 7000), (2006).
78. Heymach J.V., West H., Kerr L., Prager D., Sandler A., Herbst R., Stewart D., Dimery I., et al.: ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: results of the run-in phase of a two-part randomized phase II study. Lung Cancer 49 (Suppl 2), S247 (Abstr. P-497), (2005).
79. Heymach J., Paz-Ares L., de Braud F., Sebastian M., Stewart D.J., Eberhardt W., Herbst R.S., Krebs A., et al.: Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(18S), 395s (Abstr. 7544), (2007).
80. Heymach J.V., Johnson B.E., Prager D., Csada E., Roubec J., Pesek M., Spasova I., Belani C.P., et al.: Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J. Clin. Oncol. 25(27), 4270-4277, (2007).
81. Ciardiello F., Bianco R., Damiano V., Fontanini G., Caputo R., Pomatico G., De Placido S., Bianco A.R., et al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6(9), 3739-3747, (2000).
82. Herbst R.S., Johnson D.H., Mininberg E., Carbone D.P., Henderson T., Kim E.S., Blumenschein G. Jr., Lee J.J., et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(11), 2544-2555, (2005).
83. Herbst R.S., O'Neill V.J., Fehrenbacher L., Belani C.P., Bonomi P., Hart L., Melnyk O., Ramies D., et al.: Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 25(30), 4743-4750, (2007).
84. Van den Boogart V., de Langen A., Groen H.J., Marcus J., Kappert P., Backes W., Brans B., Hoekstra O., et al.: A phase II study of erlotinib (E) and bevacizumab (B) in chemo naive patients (pts) with locally advanced or metastatic non small cell lung cancer (NSCLC): Predictive value of molecular imaging. J. Clin. Oncol. 26(15S), 437s (Abstr. 8055), (2008).